SEC's new Innovation Exemption removed regulatory obstacles, leading to buy recommendations from Cantor Fitzgerald and Rosenblatt.
1 report, 1 independent
Updated Sep 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
SEC's new Innovation Exemption removed regulatory obstacles, leading to buy recommendations from Cantor Fitzgerald and Rosenblatt.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.
- Cantor Fitzgerald initiated coverage with an overweight rating and price target for a company debuting on the New York Stock Exchange.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald disclosed a stock transaction via SEC filing, coinciding with Donald Trump's purchase of Strategy shares in July.
- Robinhood seeks regulatory approval for tokenized stocks following an SEC Innovation Exemption order.